Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
Sponsor: The Third People's Hospital of Chengdu
Summary
This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
55
Start Date
2024-06-01
Completion Date
2025-03-31
Last Updated
2024-08-20
Healthy Volunteers
No
Conditions
Interventions
Hetrombopag
Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
Locations (1)
Chengdu Third People's Hospital
Chengdu, Sichuan, China